By Abigail Townsend
Date: Monday 11 Jan 2021
LONDON (ShareCast) - (Sharecast News) - Gilead Sciences has upped its full-year profit guidance following strong sales of its Covid-19 treatment remdesivir.
The US biopharmaceuticals firm said the improved guidance reflected "increased Veklury sales, as hospitalisation and treatment rates were higher than expected given the most recent Covid-19 surge".
Remdesivir, an antiviral sold under the brand name Veklury, has been licensed around the world to treat patients who have Covid-19. It was one of a cocktail of drugs used to treat US president Donald Trump when he tested positive for the virus.
Gilead now expects total product sales for 2020 to come in between $24.3bn and $24.35bn, compared with a previous guidance range of $23bn to $23.5bn. Non-GAAP diluted earnings per share guidance has been adjusted to between $6.98 and $7.08, compared to between $6.25 and $6.60 previously.
On a GAAP basis, the forecast has been amended from between a loss per share of $0.25 and a profit of $0.10, to between a loss per share of $0.08 and a profit of $0.02 per share.
As at 1435 GMT, shares in Gilead were trading 2% higher at 64.05p.
Gilead is due to post fourth-quarter results on 2 February.
Email this article to a friend
or share it with one of these popular networks:
Currency | US Dollars |
Share Price | $ 65.06 |
Change Today | $ 1.50 |
% Change | 2.36 % |
52 Week High | $87.29 |
52 Week Low | $62.71 |
Volume | 9,793,590 |
Shares Issued | 1,246.00m |
Market Cap | $81,065m |
RiskGrade | 120 |
Strong Buy | 4 |
Buy | 8 |
Neutral | 17 |
Sell | 1 |
Strong Sell | 0 |
Total | 30 |
Time | Volume / Share Price |
15:59 | 400 @ $65.07 |
15:59 | 300 @ $65.07 |
15:59 | 200 @ $65.07 |
15:59 | 300 @ $65.07 |
15:59 | 100 @ $65.07 |
You are here: research